INTRODUCTION {#S1}
============

Sp1 is a transcription factor that belongs to the SP/XKLF (Specificity protein/kruppel-like factor) family. Its DNA binding domain possesses three C2H2-type zinc fingers that have higher binding affinities with GC-boxes and lower binding affinities to CT and GT boxes ([@R41]). Aside from regulating gene expression by binding to its own binding sites, Sp1 appears as a versatile partner for many other transcription factors in activating or repressing its responsive genes. Sp1 was originally characterized as a transcription factor for constitutive activation of housekeeping genes. More recently, it has become clear that Sp1 also possesses regulatory function and is actively involved in tissue specific gene expression as well as responses to induced signals ([@R19]; [@R42]). Although Sp1 gene expression is ubiquitous, several studies have shown that its expression varies substantially in different cell types or the same cell type at different stage of development ([@R36]).

Human kallikrein (KLK)-related peptidase family comprises 15 secreted serine proteases (KLK1 to KLK15) that possess trypsin-like or chymotrypsin-like enzyme activities ([@R47]). To date, 8 KLK proteins, KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13, and KLK14, have been found in stratum corneum (SC) tissues and skin appendages ([@R27]; [@R28]). The KLKs function has been proposed as desquamatory enzymes by causing degradation of corneodesmosomal adhesion proteins in the SC and leading to shedding of the outmost layer of skin ([@R5]; [@R14]; [@R15]). KLKs protease activity and their corresponding inhibitors are strictly regulated under physiological conditions ([@R10]). Elevated KLKs gene expression have been found in skin diseases with skin barrier disorders such as psoriasis ([@R25]), acne rosacea ([@R43]), atopic dermatitis (AD) ([@R26]).

Human thymic stromal lymphopoietic (TSLP) is a cytokine mainly expressed by atopic epithelial cells such as keratinocytes ([@R35]). Human dendritic cells (DC), stimulated by TSLP, produce chemokines that attract T~H~2 type CD4^+^ T cells; and TSLP-treated DCs drive CD4^+^ T cells to differentiate into a T~H~2 phenotype producing IL4, IL5 and IL13 ([@R35]; [@R39]). The discovery that TSLP promotes TH2 immune responses inspired new insights into the important role of epithelium in initiating and controlling immune responses. Indeed, TSLP expression has been significantly elevated in the epidermis from patients with AD and Netherton syndrome (NS), a disease with severe AD-like skin manifestations ([@R39]; [@R6]). Interestingly, Briot et al found unstrained KLK5 in NS patients was responsible for elevated TSLP expression ([@R6]).

Recently, we found that inhibition of Sp1 gene expression enhanced vaccinia virus and herpes simplex virus (HSV) replication in keratinocytes by attenuating the anti-viral innate immune response ([@R2]). Furthermore, we found that Sp1 gene expression was significantly decreased in the skin biopsies from patients of AD. Interestingly, AD patients with a history of eczema herpeticum (ADEH) had significantly lower levels of Sp1 as compared to AD without a history of viral infection. AD is a chronic inflammatory skin disease which is characterized by elevated T~H~2 infiltration and loss of skin barrier function ([@R10]; [@R4]). ADEH subjects have more severe eczema and increased T~H~2 responses as compared to regular AD ([@R1]). The findings of Sp1 deficiency in AD and ADEH prompted us to further investigate the role of Sp1 in keratinocytes' biological processes. In this study, we reported that Sp1 silencing changed the expression profile of keratinocytes and led to up-regulation of six KLK family members. The elevated gene expression of KLKs resulted in significantly enhanced protease activity and augmentation of TSLP levels in Sp1-silenced cells. The current study indicates that epidermal Sp1 deficiency may contribute to T~H~2 immune responses in the skin by enhancing expression of TSLP in keratinocytes.

RESULTS {#S2}
=======

Inhibition of Sp1 alters gene expression profiling of Keratinocytes {#S3}
-------------------------------------------------------------------

To gain better insight into the molecular perturbations induced by reduced Sp1 expression in keratinocytes, we used a gene microarray approach to identify genes that were affected by down-regulation of Sp1. Normal human keratinocytes (NHK) were transfected with siRNA duplexes specifically targeting Sp1 or control scrambled siRNA. Sp1 mRNA levels and proteins levels in NHK were monitored up to four days after the transfection of siRNA duplexes. As shown in [Figure S1](#SD1){ref-type="supplementary-material"}, both Sp1 mRNA and protein were decreased in NHK following transfection of Sp1 siRNA duplexes at day one and this difference persisted for four days. Transfection with control scrambled siRNA didn\'t affect Sp1 expression. RNA extracted from NHK after 72 hours of transfection with siRNA duplexes was used for gene profiling studies. Three independent experiments were performed and analyzed using Affymetrix genechip human genome U133 plus 2.0 arrays. Sp1 down-regulation was associated with a substantial modification of gene transcription profiles. Using scrambled siRNA transfected cells as the reference, we found 1268 genes with unique gene symbol identifiers to be differentially expressed with greater than 1.5-fold change. The expression of 576 genes was increased whereas the expression of 692 genes was decreased. With a three-fold change of expression, 53 genes with unique gene symbol identifiers were found differentially expressed with 27 up-regulated and 26 down-regulated genes. [Table 1](#T1){ref-type="table"} shows the most up-regulated and down-regulated genes. Sp1 inhibition had an effect on the expression of many genes involved in multiple cellular functions including metabolism, inflammation, proliferation, and apoptosis, etc.

Among the top four most up-regulated genes associated with Sp1 silencing, S100A12 is known to be a proinflammatory protein that possesses chemotactic activity for monocytes and mast cells ([@R44]); Kallikrein-related peptidase 6 (KLK6) is a serine protease involved in the process of desquamation ([@R5]); vanin 3 (VNN3) is a protein belonging to the pantetheinase enzyme family that catalyzes the conversion of vitamin B5 into the antioxidant cysteamine ([@R30]; [@R31]). Expression of these three genes have been previously reported to be increased in the skin of AD patients and other allergic diseases ([@R21]; [@R25]; [@R45]). Using real-time PCR in NHK cells from three different donors and three different Sp1 siRNA duplexes, we confirmed the gene expression of these three genes are indeed up-regulated in Sp1-silenced NHK cell as compared to cells transfected with scrambled siRNA duplexes ([Figure 1](#F1){ref-type="fig"}).

Keratin 13 (KRT13) and keratin 19 (KRT19) are the top two most down-regulated genes in Sp1-silenced NHK, and keratin 15 (KRT15) was also down-regulated 3.8-fold following Sp1 silencing. Both KRT19 and KRT15 are biomarkers for skin stem cells (Pontiggia *et al*, 2009), whereas mutations in KRT13 result in white sponge naevus (WSN; OMIM 193900) ([@R37]). We confirmed that these three genes were down-regulated in Sp1-silenced NHK cells by real-time PCR in NHK from three different donors ([Figure 1](#F1){ref-type="fig"}).

Kallikrein family members are up-regulated in Sp1-silenced keratinocytes {#S4}
------------------------------------------------------------------------

Several lines of evidence have implicated KLK family members in the pathogenesis of T~H~2-mediated skin diseases including AD and Netherton syndrome (NS), a rare genetic skin disease with AD-like skin manifestations ([@R3]; [@R25]; [@R28]). Therefore, we searched further for KLK family members with expression changes following Sp1 silencing in NHK cells. We were struck by the finding that ten probes representing six KLK family members were up-regulated in Sp1-silenced NHK cells analyzed by gene profiling. As shown in [Table 2](#T2){ref-type="table"}, KLK6, KLK10, KLK12, KLK8, KLK5 and KLK7 were up-regulated to different degrees from 1.45- to 5.27-fold.

We investigated the dynamic gene expression of KLK family members up to four days following Sp1 silencing. As shown in [Figure 2](#F2){ref-type="fig"}, KLK5, KLK6, KLK7 and KLK12 were increased in expression two days after transfection of Sp1 siRNA, whereas KLK8 and KLK10 were up-regulated one day after transfection of Sp1 siRNA. However, the greatest increase of all six genes as compared to control was at three days after transfection. We also harvested protein lysates from cells after three days of silencing Sp1 and confirmed that six kinds of KLK protein levels were increased in Sp1-silenced NHK cells ([Figure S2](#SD1){ref-type="supplementary-material"}).

Protease activity is enhanced in Sp1-silenced keratinocytes but not affect skin barrier protein filaggrin (FLG) protein level {#S5}
-----------------------------------------------------------------------------------------------------------------------------

KLK proteins are secreted proteins and possess trypsin-like and chymotrypsin-like activities ([@R47]). We therefore investigated whether up-regulation of KLKs in Sp1-silenced NHK led to enhanced protease activity. As shown in [Figure 3a](#F3){ref-type="fig"}, the functional protease activity in cell culture supernatants from Sp1-silenced NHK cells was significantly increased as compared to scrambled siRNA silenced NHK cells.

Previous studies reported that human KLK5 and KLK7 degraded corneodesmosome components, desmoglein 1 (DSG1), desmocollin 1 (DSC1) and corneodesmosin (CDSN), by *in vitro* proteolysis assay ([@R7]; [@R38]). However, we didn\'t detect degradation of these proteins in Sp1-silenced NHK cells (data not shown). We then investigated whether skin barrier protein filaggrin (FLG) protein level was decreased in Sp1-silenced NHK cells after five days of Ca^2+^-drived differentiation. As shown in [Figure 3b](#F3){ref-type="fig"}, both pro-FLG and monomer FLG were not decreased in Sp1-silenced NHK cells as compared to cells transfected with scrambled siRNA. On the contrary, FLG protein level was increased in Sp1-silenced NHK as compared to cells transfected with scrambled siRNA. However, if Sp1-silenced NHK were differentiated in the presence of T~H~2 cytokines (IL4/IL13), FLG protein expression levels were suppressed.

TSLP gene expression is up-regulated in Sp1-silenced NHK depending on KLKs' protease activity {#S6}
---------------------------------------------------------------------------------------------

TSLP is thought to play a central role in atopic inflammatory diseases and it has been found to be induced by KLK5 ([@R6]; [@R13]; [@R39]). Since multiple KLK proteins were up-regulated and protease activity was enhanced in Sp1-silenced keratinocytes, we were interested in whether TSLP was up-regulated in Sp1-silenced keratinocytes. We first searched for TSLP expression in our gene array data, and found that its expression was increased in Sp1-silenced NHK by 2.7-fold as compared to controls. We further confirmed TSLP gene expression at both the mRNA and protein level. As shown in [Figure 4a](#F4){ref-type="fig"}, TSLP mRNA was significantly increased at days three and four following Sp1 silencing as compared to scrambled siRNA transfected keratinocytes. We harvested protein from cells after four days of transfection with Sp1 siRNA duplexes and found that TSLP protein was increased in Sp1-silenced keratinocytes detected by western-blot ([Figure 4b](#F4){ref-type="fig"}).

Since up-regulation of TSLP followed KLKs' Up-regulation as indicated by our time course study, we determined whether TSLP Up-regulation in Sp1-silenced NHK cells was a response to increased KLK activity. To test this hypothesis, we used a serine protease inhibitor, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), to inhibit protease activity in Sp1-silenced NHK. As shown in [Figure 4c](#F4){ref-type="fig"}, TSLP Up-regulation was significantly inhibited in Sp1-silenced NHK cells along with increased concentration of AEBSF. To further define whether TSLP up-regulation is a secondary response to increased KLKs' production, we used neutralizing antibodies to block the effects of the 6 up-regulated KLKs in Sp1 silenced NHK. As shown in [Figure 4d](#F4){ref-type="fig"}, TSLP wasn\'t up-regulated in Sp1 silenced NHK cells in the presence of KLK neutralizing antibodies. Thus, TSLP up-regulation in Sp1-silenced NHK was dependent on augmented KLK protease activity.

DISCUSSION {#S7}
==========

The goal of the current study was to advance our understanding of the biological consequence of keratinocyte deficiency of Sp1 expression. In this paper, we demonstrated that six KLK family members, KLK5, KLK6, KLK7, KLK8, KLK10 and KLK12, were significantly increased in Sp1-silenced keratinocytes. The functional significance of our gene expression data was supported by the observation of enhanced functional protease activity. TSLP gene expression was also significantly augmented in Sp1-silenced NHK. As growing evidence has shown that enhanced protease activity in the epidermis is detrimental to skin barrier function and TSLP orchestrates allergic inflammation ([@R12]; [@R16]; [@R18]; [@R48]), our findings suggest that Sp1 epidermal deficiency may play a role in allergic skin diseases such as AD and ADEH.

Among the KLKs expressed in the skin, only KLK5 (a tryptic enzyme) and KLK7 (a chymotryptic enzyme) have been studied in great detail in terms of their enzymatic activities and substrates ([@R10]). *In vitro* experiments have shown that KLK5 and KLK7 can degrade desmosomal adhesion proteins including DSG 1, CDSN and DSC 1 ([@R7]). Their enzymatic activities can be affected by pH and the presence of serine protease inhibitors ([@R11]). Of note, seven KLKs proteins, including KLK5, KLK6, KLK7, KLK8, KLK10, KLK13 and KLK14, have been found to be elevated in the SC of patients with AD ([@R26]). However, the mechanism by which KLKs are up-regulated in AD is incompletely understood. Mutations in the serine protease inhibitor Kazal-type 5 (*SPINK5*) gene has been reported in patients with NS ([@R3]; [@R8]). SPINK5 encodes the protein of the lymphoepithelial Kazal-type 5 serine protease inhibitor (LEKTI), which is a specific inhibitor of KLK5, KLK7 and KLK14. Broit *et al.* have recently demonstrated that hyperactivity of KLK5 in LEKTI deficient keratinocytes of patients with NS plays a key role in causing atopic skin lesions, thus highlighting the clinical significance of enhanced epidermal serine protease' activity in the pathogenesis of NS ([@R6]). The reports of SPINK5 mutations in NS have attracted several groups to investigate the association of SPINK5 gene variants in AD ([@R17]; [@R20]; [@R22]; [@R23]; [@R24]; [@R32]; [@R33]; [@R40]). However, their results were contradictory, suggesting that SPINK5 genetic variants only partially account for genetic predisposition to AD. We propose that epidermal deficiency of Sp1 in AD and ADEH may be an additional mechanism leading to elevated KLKs in patients with AD.

Our data also support Broit *et al*\'s finding that increased serine protease activity significantly augments TSLP gene expression in keratinocytes. This is an important confirmatory finding since TSLP is a critical cytokine that promotes T~H~2 cell development in the pathogenesis of AD ([@R48]). TSLP treated dendritic cells induce naïve CD4^+^ T cells to undergo proliferation and differentiation into T~H~2 lymphocytes, leading to enhanced production of IL-4, IL-5, and IL-13 ([@R39]). Transgenic mice overexpressing TSLP specifically in keratinocytes develop spontaneous AD disease ([@R46]). TSLP gene expression is elevated in the epidermis of patients with AD and NS ([@R6]; [@R39]).

Aside from KLKs and TSLP, several other genes that are differentially expressed in Sp1-silenced NHK, have also been implicated in the pathogenesis of AD. In this study, it was found that S100A12, a chemoattractant for monocytes and mast cells ([@R44]), is the most up-regulated gene following Sp1 silencing. Of interest, a recent study demonstrated that S100A12 induces degranulation of mast cells and amplifies IgE-mediated responses, implicating its involvement in allergic inflammatory response ([@R45]). Vanin3 (VNN3), another gene that we found is also greatly up-regulated following Sp1 silencing, has been reported to be significantly increased in AD skin lesions ([@R21]). The biological function of VNN3 in skin, however, is still not clear. Our gene array data in [Table 1](#T1){ref-type="table"} also showed down-regulation of Cornulin (CRNN) in Sp1-silenced HNK. Since the CRNN gene is located in the epidermal differentiation complex (EDC) gene cluster and its protein is found mainly in the granular layer of the epidermis ([@R9]), it is considered to be a marker of late epidermal differentiation. CRNN is significantly down-regulated in the skin of patients with AD ([@R29]).

Taken together, reduced Sp1 leads to a unique pattern of altered gene expression which mimics some of the dysregulatory features of AD skin. Importantly, we have demonstrated Sp1 deficiency leads to enhanced protease activity and over-production of the major pro- T~H~2 cytokine, TSLP, in keratinocytes; to our knowledge this is previously unreported. Although we didn\'t detect the degradation of DSG1, DSC1, CSDN, as well as FLG in Sp1-silenced NHK, we showed that T~H~2 cytokines treatment can suppress FLG protein expression in Sp1-silenced NHK. These results suggest that Sp1 deficiency in the skin of patients with AD and ADEH may contribute to the pathogenesis of these complex skin diseases by inducing TSLP, which in term promotes the elevation of T~H~2 cytokines.

METHODS {#S8}
=======

Keratinocytes culture {#S9}
---------------------

NHKs were purchased from Cascade Biologics/Invitrogen (Portland, OR) and maintained in serum free EpiLife Medium containing 0.06 mM CaCl~2~ and S7 supplemental reagent (Cascade Biologics/Invitrogen) under standard tissue culture conditions.

Small interfering RNAs (siRNAs) silencing experiment and serine protease inhibitor treatment {#S10}
--------------------------------------------------------------------------------------------

Sp1 and Silencer Negative control 1 siRNA duplexes were purchased from Ambion (Austin, TX). Sequences for targeting Sp1were as follows: Sp1 \#1 siRNA: 5\'-GCAAC AUGGGAAUUAU GAA-3\'; Sp1 \#2 siRNA: 5\'- GGCAGACCUUUACAACUCA-3\'; Sp1 \#3 siRNA: 5\'- CCACAAGCCCAAACAAUCA-3\'. NHK cells were plated in 24 well plates at 1x10^5^ per well the day before transfection. Cells were transfected with siRNA duplexes at final concentration of 10 nM using lipofectamine 2000 according to the manufacturer\'s instructions (Invitrogen, Carlsbad, CA). Sp1 \#1 siRNA was used if there was no indication. Serine protease inhibitor, AEBSF, was purchased from Sigma-Aldrich (St Louis, MO). AEBSF 6-20 M was added to NHK cells after overnight incubation with Sp1 siRNA duplexes, the cells were then incubated with AEBSF for two days. Mouse IgG~2A~ isotype control, mouse IgG2B isotype control, monoclonal anti-human KLK5, KLK6, KLK7, KLK8, KLK10 and KLK12 were purchased from R&D systems, Inc. (Minneapolis, MN). 1 μg/ml of each KLK antibody or 5 μg/ml of each KLK antibody were added to Sp1-silenced NHK cells for three days, 6 μg/ml or 30 μg/ml mixed mouse IgG~2A~ and IgG~2B~ as controls.

RNA isolation and real-time PCR {#S11}
-------------------------------

Total RNA was isolated from cells using RNeasy Mini Kits (Qiagen, Valencia, CA) according to the manufacturer\'s guidelines. RNA was reverse transcribed into cDNA using superScript® III reverse transcriptase from Invitrogen (Portland, OR) and analyzed by real time RT-PCR using an ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, CA) as previously described ([@R34]). Primers and probes for human Sp1, KLK5, KLK6, KLK7, KLK8, KLK10, KLK12, KRT13, KRT15, KRT19, VNN3, S100A12 and 18S were purchased from Applied Biosystems (Foster City, CA). Quantities of all target genes in test samples were normalized to the corresponding 18S levels.

Gene microarray analysis {#S12}
------------------------

The microarrays used for this study were Human Genome U 133 plus 2.0 arrays (Affymetrix, Santa Clara, CA) containing probe sets of 54,000 transcripts. Total RNA (5 μg) isolated from Sp1-silenced NHK cells and scrambled siRNA transfected NHK cells was converted to double-stranded cDNA and then to biotinylated cRNA. After fragmentation and quality confirmation, 15 μg of biotinylated cRNA was hybridized to microarrays. After washing and staining with streptavidin-phycoerythrin, the arrays were scanned with a Gene-array scanner (Hewlett Packard, Palo Alto, CA). Data were analyzed with Affymetrix Microarray Suite 5.0 software and GeneSpring 10.5 software.

Western-blot {#S13}
------------

Whole-cell extracts were prepared in the presence of 1% (vol/vol) of protease inhibitor cocktail and 1% (vol/vol) of phosphatase inhibitor cocktail (Sigma-Aldrich). Protein was then separated using SDS-PAGE and then transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA ). The blots were then blocked and incubated with primary and secondary antibodies. Rabbit anti-human Sp1, Rabbit anti-human TSLP, and rabbit anti-human GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-FLG monoclonal antibody was purchase from Vector Laboratories Inc. (Burlingame, CA) and mouse anti-β-actin was from Sigma-Aldrich (St. Louis, MO). Blots were developed with ECL Detection Reagents (GE Healthcare Bio-Sciences, Piscataway, NJ).

Protease activity assay {#S14}
-----------------------

Protease activity in cell culture supernatants was measured with EnzChek Protease Assay Kit green fluorescence (Molecular Probes/Invitrogen) according to manufacturer\'s instruction. Briefly, cell supernatants from HNK cells with treatment of different siRNA duplexes were mixed with same volume of BODIPY FL casein substrate in 10 mM Tris-HCl, pH 7.8, and incubated at 37°C for 48 hours. Fluorescence intensity was measured at excitation/emission of approximately 505/513. Protease activity was determined as increased fluorescence intensity.

Statistical Analysis {#S15}
--------------------

All statistical analysis was conducted using Graph Pad prism, version 5.03 (San Diego, CA). Comparisons of expression levels were performed using analysis of variance (ANOVA) techniques and independent sample *t* tests as appropriate. Differences were considered significant at *P*\<0.05.

Supplementary Material {#SM}
======================

**Supplemental Figure 1**. Sp1 gene expression is inhibited following transfection of Sp1 siRNA duplexes. NHK cells were transfected with scrambled siRNA and Sp1\#1 siRNA duplexes. Sp1 mRNA (**a**), and protein expression (**b**), were monitored from one day up to four days following siRNA transfection.

**Supplemental Figure 2**. KLK5, KLK6, KLK7, KLK8, KLK10, KLK12 protein levels were increased in Sp1-silenced NHK cells. Cell lysates were harvested at day 3 after Sp1 silencing with final 4 hours' incubation with Golgi-stop.
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AD

:   Atopic dermatitis

ADEH

:   Atopic dermatitis with a history of eczema herpeticum

AEBSF

:   4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride

CDSN

:   Corneodesmosin

CRNN

:   Cornulin

DSG 1

:   Desmoglein 1

DSC 1

:   Desmocollin 1

DC

:   Dendritic cells

EDC

:   Epidermal differentiation complex

EH

:   Eczema herpeticum

FLG

:   Filaggrin

GAPDH

:   Glyceraldehyde 3-phosphate dehydrogenase

HSV

:   Herpes simplex virus

KLK

:   Kallikrein-related peptidase

KRT

:   Keratin

LEKTI

:   Lymphoepithelial Kazal-type 5 serine protease inhibitor

NHK

:   Normal human keratinocytes

NS

:   Netherton syndrome

SC

:   Stratum corneum

SPINK5

:   Serine protease inhibitor Kazal-type 5

siRNA

:   Small interfering RNA

Sp1

:   Specificity protein 1

TSLP

:   Thymic stromal lymphopoietin

VNN3

:   Vanin 3

![Confirmation of differentially expressed genes revealed by gene profiling\
NHK cells were transfected with scrambled siRNA duplexes and three different Sp1 siRNA duplexes for three days. mRNA levels of KLK6, S100A12, VNN3, KRT19, KRT13 and KRT15 were measured by quantitative real-time PCR. Data are shown as mean ± s.e.m. Results are representative of three experiments. \* *P* \<0.05; \*\* *P* \<0.01; \*\*\* *P* \<0.001](nihms-303969-f0001){#F1}

![The dynamic changes of KLK gene expression following Sp1 silencing in NHK cells as compared to the control\
mRNA levels of KLK5, KLK6, KLK7, KLK8, KLK10 and KLK12 were measured by quantitative real-time PCR from one day up to four days after transfection of Sp1 and scrambled siRNA duplexes. Data are presented as mean ± s.e.m. Results are representative of three experiments. \* *P* \<0.05; \*\* *P* \<0.01; \*\*\* *P* \<0.001](nihms-303969-f0002){#F2}

![Sp1 silencing leads to enhanced protease activity but not degradation of FLG\
**a)** NHK cells were transfected with scrambled siRNA duplexes and three different Sp1 siRNA for three days. Culture supernatants were incubated with fluorescence--conjugated casein substrate for 48 hours, and protease activity was determined based on the generation of fluorescent product from this substrate as described in Material and Methods. Data are presented as mean ± s.e.m of triplicate experiments. \*\* *P*\<0.01 **b)** FLG protein expression was detected by western blot. NHK cells were transfected with scrambled siRNA duplexes and three different Sp1 siRNA and differentiated at 1.3mM Ca^2+^ in the absence and presence of IL4/IL13 for five days.](nihms-303969-f0003){#F3}

![TSLP gene expression is up-regulated in Sp1-silenced NHK depending on enhanced protease activity\
**a)** TSLP mRNA is significantly increased at days three and four following Sp1 silencing as compared to NHK transfected with scrambled siRNA. **b)** TSLP protein was detected by western-blot in NHK four days after transfection of siRNA duplexes. **c)** NHK cells were transfected with scrambled siRNA and Sp1 siRNA duplexes in the absence and presence of protease inhibitor AEBSF for three days. mRNA levels of TSLP were measured by quantitative real-time PCR. d) NHK cells were transfected with scrambled siRNA and Sp1 siRNA duplexes in the absence and presence of six anti-KLK neutralizing antibodies and isotype control IgG for three days (see methods for details). mRNA levels of TSLP were measured by quantitative real-time PCR. Data are presented as mean ± s.e.m of triplicate experiments. \*\* *P* \<0.01;\*\*\* *P*\<0.001.](nihms-303969-f0004){#F4}

###### 

Genes affected by Sp1 silencing

  Affymetrix ID                                      Symbol            Full name                                                                             Relative Intensity (mean±SEB)   Fold Change     *p* value   
  -------------------------------------------------- ----------------- ------------------------------------------------------------------------------------- ------------------------------- --------------- ----------- ----------------------------------------
  **Metabolism**                                                                                                                                                                                                         
  212816_s\_at                                       CBS               Cystathionine-beta-synthase                                                           76.97 ± 17.94                   463.1± 169.8    6.02        ns
  206643_at                                          HAL               Histidine ammonia-lyase                                                               539.4 ± 20.38                   2521 ± 140.2    4.67        ^[\*\*](#TFN2){ref-type="table-fn"}^
  206177_s\_at                                       ARG1              Arginase, liver                                                                       646.5 ± 55.23                   2667 ± 348.5    4.12        ^[\*](#TFN1){ref-type="table-fn"}^
  217127_at                                          CTH               Cystathionase (cystathionin e gamma-lyase                                             286.7 ± 82.59                   1056 ± 172.6    3.68        ns
  211788_s\_at                                       TREX              Three prime repair exonuclease 2                                                      155.4 ± 11.99                   564.2± 31.81    3.63        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  231202_at                                          ALDH1L2           Aldehyde dehydrogenase 1 family, member L2                                            21.67 ± 4.486                   85.3 ± 28.12    3.94        ns
  203438_at                                          STC2              Stanniocalcin 2                                                                       214.9 ± 67.02                   670.8± 124.8    3.12        ^[\*](#TFN1){ref-type="table-fn"}^
  205047_s\_at                                       ASNS              Asparagine synthetase                                                                 873.8 ± 224.7                   2999 ±825.5     3.43        ns
  238029_s\_at                                       SLC16A14          Solute carrier family 16, member 14 (monocarboxylic acid transporter 14)              10.53 ± 1.364                   34.97±3.597     3.32        ^[\*\*](#TFN2){ref-type="table-fn"}^
  208126_s\_at                                       CYP2C18           Cytochrome P450, family 2, subfamily C, polypeptide 18                                71.33 ± 2.483                   218.3± 15.59    3.06        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  224009_x\_at                                       DHRS9             Dehydrogenase/reductase (SDR family) member 9                                         390.6 ± 16.85                   1213 ± 197.8    3.10        ^[\*](#TFN1){ref-type="table-fn"}^
  208998_at                                          UCP2              Uncoupling protein 2 (mitochondrial, proton carrier)                                  955.4 ± 2.776                   196.9 ± 17.97   -4.85       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  223044_at                                          SLC40A1           Solute carrier family 40 (iron-regulated transporter), member 1                       232.0 ± 7.365                   54.43 ± 9.879   -4.26       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  210519_s\_at                                       NQO1              NAD(P)H dehydrogenase, quinine 1                                                      1724 ± 32.77                    501.5 ± 44.00   -3.43       ^[\*\*](#TFN2){ref-type="table-fn"}^
  206561_s\_at                                       AKR1B10           Aldo-keto reductase family 1, member B10 (aldose reductase)                           563.5 ± 35.33                   171.3 ± 18.33   -3.29       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  201042_at                                          TGM2              Transglutaminase 2(C polypeptide, protein-glutamine-gamma-glutamyltransferase)        296.4 ± 21.87                   92.30 ± 13.51   -3.21       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Cell growth and apoptosis**                                                                                                                                                                                          
  215785_s\_at                                       CYFIP2            Cytoplasmic FMR1 interacting protein 2                                                71.40 ± 3.544                   275.6 ± 22.37   3.85        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  226492_at                                          SEMA6D            Sema domain, transmembrane domain(TM), and cytoplasmic domain, (semaphorin) 6D        49.83 ± 5.912                   13.20 ± 1.464   -3.77       ^[\*\*](#TFN2){ref-type="table-fn"}^
  202409_at                                          IGF2///INS-IGF2   Insulin-like growth factor 2 (somatomedin A)/// INS-IGF2 readthrough transcript       2082 ± 37.40                    597.7 ± 37.49   -3.48       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  211959_at                                          IGFBP5            Insulin-like growth factor binding protein 5                                          98.93 ± 15.52                   29.27 ± 4.53    -3.38       ^[\*](#TFN1){ref-type="table-fn"}^
  1552701_a\_at                                      CARD16            Caspase recruitment domain family, member 16                                          320.9 ± 26.74                   89.83 ± 8.07    -3.57       ^[\*\*](#TFN2){ref-type="table-fn"}^
  205081_at                                          CRIP1             Cysteine-rich protein 1 (intestinal)                                                  164.0 ± 9.40                    47.57 ± 0.38    -3.44       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Transcription facto**r                                                                                                                                                                                               
  236265_at                                          SP4               Sp4 transcription factor                                                              135.3 ± 9.734                   517.3 ± 57.95   3.82        ^[\*\*](#TFN2){ref-type="table-fn"}^
  **Inflammation**                                                                                                                                                                                                       
  205863_at                                          S100A12           S100 calcium binding protein A12                                                      101.8± 5.4                      690.6 ± 9.04    6.78        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  220528_at                                          VNN3              Vanin 3                                                                               27.00 ± 0.51                    152.3 ± 15.09   5.64        ^[\*\*](#TFN2){ref-type="table-fn"}^
  **Receptor and transmembrane protein**                                                                                                                                                                                 
  204007_at                                          FCGR3B            Fc fragment of IgG, low affinity IIIb, receptor (CD16b)                               36.37 ± 4.70                    242.0 ± 42.53   6.65        ^[\*\*](#TFN2){ref-type="table-fn"}^
  221107_at                                          CHRNA9            Cholinergic receptor, nicotinic, alpha 9                                              44.60 ± 0.70                    190.7 ± 33.45   4.27        
  228176_at                                          SIPR3             Sphingosine-1-phosphate receptor 3                                                    101.8 ± 9.18                    24.30 ± 3.24    -4.19       ^[\*\*](#TFN2){ref-type="table-fn"}^
  **Mucus secretion**                                                                                                                                                                                                    
  209173_at                                          AGR2              Anterior gradient homolog 2 (Xenopus laevis)                                          321.4 ± 11.59                   106.7 ± 8.23    -3.01       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Membrane protein**                                                                                                                                                                                                   
  219313_at                                          GRAMDIC           GRAM domain containing 1C                                                             43.00 ± 0.15                    146.1 ± 20.22   3.40        ^[\*\*](#TFN2){ref-type="table-fn"}^
  229927_at                                          LEMD1             LEM domain containing 1                                                               129.2 ± 10.31                   26.07 ± 1.24    -4.96       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  232176_at                                          SLITRK6           SLIT and NTRK-like family, member 6                                                   134.8 ± 5.48                    35.00 ± 8.96    -3.85       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  228080_at                                          LAYN              Layilin                                                                               184.9 ± 3.89                    53.13 ± 4.30    -3.48       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  214297_at                                          CSPG4             Chondroitin sulfate proteoglycan 4                                                    182.0 ± 6.53                    55.67 ± 12.32   -3.27       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  220090_at                                          CRNN              Cornulin                                                                              98.43 ± 9.19                    31.30 ± 2.89    -3.14       ^[\*\*](#TFN2){ref-type="table-fn"}^
  **Epidermis development /intermediate filament**                                                                                                                                                                       
  207935_s\_at                                       KRT13             Keratin 13                                                                            4027 ± 154.0                    515.7 ± 108.7   -7.81       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  201650_at                                          KRT19             Keratin 19                                                                            2149 ± 163.7                    309.4 ± 88.33   -6.95       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  204734_at                                          KRT15             Keratin 15                                                                            3911 ± 155.2                    1067 ± 230.4    -3.66       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Extracellular matrix**                                                                                                                                                                                               
  206101_at                                          ECM2              Extracellular matrix protein 2, female organ and adipocyte specific                   56.73 ± 12.23                   253.9 ± 71.26   4.48        ns
  208978_at                                          CRIP2             Cysteine-rich protein 2                                                               1431 ± 52.16                    455.8 ± 65.88   -3.14       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  211964_at                                          COL4A2            Collagen, type IV, alpha 2                                                            360.7 ± 18.67                   111.2 ± 7.16    -3.24       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Wnt signaling pathway**                                                                                                                                                                                              
  202036_s\_at                                       SFRP1             Secreted frizzled-related protein 1                                                   178.8 ± 44.04                   55.97 ± 6.56    -3.20       ns
  **Serine protease**                                                                                                                                                                                                    
  204733_at                                          KLK6              Kallikrein-related peptidase 6                                                        80.87 ± 2.30                    463.1 ± 39.02   5.72        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Protease inhibitor**                                                                                                                                                                                                 
  202833_s\_at                                       SERPINA1          Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1   68.03 ± 1.62                    18.37 ± 0.86    -3.70       ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  **Unknown function**                                                                                                                                                                                                   
  1558212_at                                         FLI35024          Hypothetical LOC401491                                                                27.97 ± 2.97                    118.4 ± 31.6    4.23        ^[\*](#TFN1){ref-type="table-fn"}^
  227410_at                                          FAM43A            Family with sequence similarity 43, member A                                          172.0 ± 10.24                   650.7 ± 70.41   3.78        ^[\*\*](#TFN2){ref-type="table-fn"}^
  230765_at                                          KIAA1239          KIAA1239                                                                              32.63 ± 2.85                    117.5 ± 16.24   3.60        ns
  226905_at                                          FAM101B           Family with sequence similarity 101, member B                                         187.2 ± 17.27                   638.0 ± 65.02   3.41        ^[\*](#TFN1){ref-type="table-fn"}^
  232689_at                                          LOC284561         Hypothetical protein LOC284561                                                        31.10 ± 4.82                    112.7 ± 31.41   3.62        ^[\*\*\*](#TFN3){ref-type="table-fn"}^
  1558195_at                                         LOC283404         Hypothetical protein LOC283404                                                        121.2 ± 9.83                    402.8 ± 65.64   3.32        ^[\*\*](#TFN2){ref-type="table-fn"}^
  226723_at                                          CCDC23            Coiled-coil domain containing 23                                                      299.3 ± 9.36                    908.3 ± 69.25   3.03        ^[\*\*](#TFN2){ref-type="table-fn"}^
  218723_s\_at                                       C13orf15          Chromosome 13 open reading frame 15                                                   187.6 ± 19.75                   32.73 ± 5.55    -5.73       ^[\*\*](#TFN2){ref-type="table-fn"}^
  236984_at                                          C4orf26           Chromosome 4 open reading frame 26                                                    32.20 ± 1.79                    10.63 ± 1.22    -3.03       ^[\*\*](#TFN2){ref-type="table-fn"}^

Genes identified by microarray analysis (Affymetrix GeneChip Human Genome U133. plus two) have greater than three-fold of Up-regulation or downregulation following Sp1 silencing in NHK (three independent experiments). Differential gene expression following Sp1 silencing relative to control was determined by GeneSpring GX 7.3 statistical analysis module ANOVA and *t* test. ns, no significance

*P*\<0.05

*P*\<0.01

*P*\<0.001.

###### 

KLK family members are up-regulated in Sp1 silenced keratinocytes

  Probe set       Gene name       Relative Intensity (mean ±SEM)   Ratio (Sp1siRNA/Scrambled siRNA   p value   
  --------------- --------------- -------------------------------- --------------------------------- --------- ----------------------------------------
  204733_at       KLK6            88.88 ± 4.02                     425.95 ± 67.56                    5.27      ^[\*\*\*](#TFN6){ref-type="table-fn"}^
  215808_at       KLK10           53.46 ± 6.04                     187.17 ± 69.40                    3.5       ^[\*](#TFN4){ref-type="table-fn"}^
  220782_x\_at    KLK12           85.39 ± 7.17                     233.29 ± 13.00                    2.73      ^[\*\*\*](#TFN6){ref-type="table-fn"}^
  233687_s\_at    KLK8 /// KLK9   47.97 ±8.30                      112.87 ± 6.54                     2.35      ^[\*\*\*](#TFN6){ref-type="table-fn"}^
  234316_x\_at    KLK12           96.42 ± 7.28                     219.07 ± 32.08                    2.27      ^[\*\*](#TFN5){ref-type="table-fn"}^
  209792_s\_at    KLK10           3541.23 ± 320.10                 6723.03 ± 415.80                  1.9       ^[\*\*\*](#TFN6){ref-type="table-fn"}^
  1552319_a\_at   KLK8            219.66 ± 5.91                    363.16 ± 22.27                    1.65      ^[\*\*\*](#TFN6){ref-type="table-fn"}^
  222242_s\_at    KLK5            4633.18 ± 599.77                 7657.66 ± 160.40                  1.65      ^[\*\*](#TFN5){ref-type="table-fn"}^
  205778_at       KLK7            3077.18 ± 306.69                 4459.33 ± 759.10                  1.45      ^[\*](#TFN4){ref-type="table-fn"}^
  239381_at       KLK7            2275.83 ± 72.40                  3542.96 ± 102.97                  1.56      ^[\*\*\*](#TFN6){ref-type="table-fn"}^

Genes identified by microarray analysis (Affymetrix GeneChip Human Genome U133 plus 2).

*P*\<0.05

*P*\<0.01

*P*\<0.001
